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SCC developed in 26/312 exposed to vori and in 1/69 who
received alternative antifungals. Cumulative incidence of
SCC at 1 year was 3%, 2 years was 8%, 3 years was 13%, 4
years was 14%, and at 5 years was 19% (ﬁgure 1).
Cumulative days of vori use was found to be a risk factor
for the development of SCC, and this relationship persisted
in a multivariate model using previously identiﬁed risk
factors (gender, age at transplant, TBI , skin cancer pre-
HSCT, GVHD) as covariates (HR 1.859 for each 180 days of
use, p<0.001). History of prior vori exposure was not
associated with increased risk of SCC after covariate
adjustment (HR 2.436, p¼0.2369).
Conclusion: This is the ﬁrst study to establish cumulative
days of vori use as a risk factor for SCC development
following allo-HSCT, and may help guide appropriate anti-
fungal prophylaxis in this patient population which is
already at an increased risk of developing skin cancers.352
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Human herpesvirus 6 type B (HHV-6B) is an important
opportunistic pathogen in immunocompromised patients.
Approximately 95% of adults have evidence of past infection,
and HHV-6B reactivation occurs in approximately 30-80% of
allogeneic hematopoietic stem cell transplantation (HCT)
recipients 2-6 weeks after transplantation. HHV-6B has beenFig.1. Quantitative plasma human herpesvirus 6 (HHV-6) viral loads (VL) and liver en
phosphatase.associated with a variety of diseases that result in signiﬁcant
morbidity and mortality. We report a case of acute hepatitis
likely caused by HHV-6B in a HCT recipient who was suc-
cessfully treated with ganciclovir.
There are multiple reports of HHV-6B-associated hepatitis
following primary HHV-6 infection and liver transplantation,
but it has been well documented in only one patient after
HCT. We cared for a 23-year-old man with sickle cell disease
who underwent a matched related myeloablative HCT. His
early post-transplant course was notable for CMV reac-
tivation and gastrointestinal graft-versus-host disease for
which he completed treatment with ganciclovir and steroids,
respectively. He was admitted on D+98 for evaluation of
epigastric abdominal pain.
Initial work up was largely unremarkable, but he underwent
uncomplicated cholecystectomy on D+103 for persistent
symptoms and ultrasonographic evidence of cholelithiasis.
While recovering, new right upper quadrant tenderness, fe-
ver and transaminitis developed (Fig. 1). Extensive workup
was negative except for plasma PCR for HHV-6B DNA
(170,000 copies/mL) on D+108, and he was started on gan-
ciclovir 5 mg/kg intravenously every 12 hours. Donor and
patient testing for chromosomally integrated HHV-6 was
negative. Liver biopsy on D+113 revealed non-speciﬁc lobular
hepatitis. PCR of biopsy samples were negative for CMV, EBV,
adenovirus and HHV-7 but positive for HHV-6 (180,000
copies/reaction). Transaminases peaked at AST 719 IU/mL,
ALT 814 IU/mL and AP 378 IU/mL on D+112 and returned to
baseline on D+122. HHV-6B viral load decreased to <5,000
copies/mL by D+115. He defervesced but had mild persistent
abdominal pain at discharge. Retrospective immunohisto-
chemical stains for multiple anti-HHV-6 antibodies localized
to hepatocytes and Kupffer cells, consistent with active
infection (Fig. 2).
Determining the cause of organ dysfunction after HCT is
challenging. This is the second reported case of likely HHV-
6B-associated hepatitis following HCT, which may be an
underappreciated cause of liver disease in this population.
Prompt testing and initiation of treatment for HHV-6 afterzyme trends during hospitalization. ALT, alanine aminotransferase; AP, alkaline
Fig. 2. Immunohistochemical staining (brown) of a number of HHV-6 proteins.
A) Early antigen (E A) p41 staining in the cytoplasm of hepatocytes and Kupffer cells (20X). Inset shows positively staining bodies in the cytoplasm of hepatocytes
(60X) [bar ¼ 100 mM]. B) EA p41 staining of control liver specimen with hemosiderosis showing light background staining in hepatocytes but not in Kupffer cells. C)
Viral capsid antigen (VCA) p140 staining in Kupffer cell cytoplasm, and in a punctate distribution in hepatocyte cytoplasm, both with a patchy distribution. D) VCA
stained control with hemosiderosis showing minimal background staining. E) Envelope glycoprotein (EG) gH stains similarly to VCA with an identical patchy dis-
tribution. F) CD68 staining of the subject liver demonstrating Kupffer cells.
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patient. It is reasonable to consider treating HHV-6 in the
setting of reactivation and hepatitis while diagnostic workup
is underway.353
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Background: Human herpesvirus 6 (HHV-6) reactivates in
33-48% of hematopoietic stem cell transplant (HCT) re-
cipients and is associated with numerous adverse effects.HHV-6 chronically infects cells after primary infection and
has a unique ability to integrate into chromosomal telo-
meres. If this occurs in germ cell lines, vertical transmission
results in individuals with chromosomally integrated HHV-6
(ciHHV-6) in every nucleated cell. Studies have found ciHHV-
6 in an average of 0.85% of blood donors and 1.99% of patient
groups (Rev. Med. Virol. 2012; 22: 144e155). A few reports
suggest that patients with ciHHV-6 can develop in vitro and
in vivo HHV-6 replication and disease. The prevalence of
ciHHV-6 in patients with HHV-6-associated diseases is un-
known and may provide insight into the risk for pathologic
HHV-6 reactivation.
Methods: To determine the prevalence of ciHHV-6 in pa-
tients with HHV-6 end-organ disease, we identiﬁed cases of
HHV-6-associated post-stem cell transplant acute limbic
encephalitis (HHV-6-PALE) and tested patients and their
donors for ciHHV-6. HHV-6-PALE was diagnosed in patients
with HHV-6 DNA in cerebrospinal ﬂuid (CSF) and neurologic
symptoms with no other explanatory etiology. CiHHV-6 was
identiﬁed in blood samples by testing extracted DNA for
HHV-6 and a reference gene for cell count with droplet
digital PCR. Positive samples had a ratio of 1  0.07 HHV-6/
genome equivalents.
